Search Result

Results for "

tyrosine-decarboxylase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Autophagy (1) Bcl-2 Family (1) Endogenous Metabolite (1) GLP Receptor (1) Insulin Receptor (1) Isotope-Labeled Compounds (1) p38 MAPK (1) α-synuclein (1)
By Research Areas:	Cancer (2) Metabolic Disease (2) Neurological Disease (1)

Inhibitors & Agonists

Peptides

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: Amino Acid Decarboxylase Ornithine decarboxylase (ODC) Tyrosine Hydroxylase Malonyl-CoA Decarboxylase Btk Syk DYRK Pyk2 TNK1 BRK FAK FLT3 Anaplastic lymphoma kinase (ALK)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P2825

Tyrosine decarboxylase, Microorganism TDC; TyrDC	Endogenous Metabolite	Metabolic Disease Cancer
Tyrosine decarboxylase, Microorganism (TDC) widely exists in plants, insects and different microorganisms, and is often used in biochemical research. Tyrosine decarboxylase is a pyridoxal 5'-phosphate (PLP)-dependent decarboxylase that catalyzes the removal of carboxyl groups from tyrosine to produce tyramine and carbon dioxide .

HY-114118S

Semaglutide-d8	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Cat. No.	Product Name	Target	Research Area

HY-114118S

Semaglutide-d8	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Tag:	His (1) Tag Free (1) Flag (1)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P702097

	tdc Protein, Levilactobacillus brevis tdc; L-tyrosine decarboxylase; TDC	Others	E. coli
	TDC protein plays a key role in amino acid metabolism by catalyzing the decarboxylation of L-tyrosine to produce tyramine. TDC is specific and does not utilize other aromatic L-amino acids such as L-phenylalanine, L-tryptophan, and L-glutamate as substrates. tdc Protein, Levilactobacillus brevis is the recombinant tdc protein, expressed by E. coli , with tag free.

HY-P702096

	tdc Protein, Levilactobacillus brevis (FLAG, His) tdc; L-tyrosine decarboxylase; TDC	Others	E. coli
	TDC protein plays a key role in amino acid metabolism by catalyzing the decarboxylation of L-tyrosine to produce tyramine. TDC is specific and does not utilize other aromatic L-amino acids such as L-phenylalanine, L-tryptophan, and L-glutamate as substrates. tdc Protein, Levilactobacillus brevis (FLAG, His) is the recombinant tdc protein, expressed by E. coli , with N-6*His, N-Flag labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-114118S

Semaglutide-d8
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Semaglutide-d8

Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.